Vol. 7 (05) pp. 1218-1225 DOI: 10.21474/IJAR01/9154

HET CAM IRRITANCY STUDY FOR DEVELOPMENT OF GATIFLOXACIN IN SITU GEL FORMULATION.

and
83 Downloads 201 Views
Crossref

Download Full Paper (PDF)

Abstract

Purpose: Formulation and evaluation of annon irritant ion activated in situ gel of a flouroquinolone antibiotic, Gatifloxacin. Methods: Ion activated in situ gel formulation was developed using Gellan gum as phase transition polymer and HPMC K 100M as release retardant which can undergo a sol-gel transition in the cul-de-sac of the eye. Results:Gatifloxacin in situ gel formulation with pH 6.0-6.3 and 52 cps in solution form resulted in gel formation in simulated lacrimal fluid having 325 cps viscosity, indicating phase transition behaviour in physiological conditions of eye. It was found to be isotonic, as it exhibited no change in the size and shape of RBCs. Formulation was found to be non irritant to eyes exhibiting mean score of zero in HET-CAM (Hen?s Egg Test ChorioAllantoic Membrane) test for ocular irritancy for 5 min Conclusion: It can be concluded that the developed in situ gel formulation can be viewed as a better alternative to the conventional eye drops of Gatifloxacin by virtue of its ability to enhance pre corneal residence time and consequently ocular bioavailability with lesser frequency of administration.

Keywords

Article Analytics

References

  1. Vengurlekar P, Singh A, Rathod S. Microspheric in situ gel for ocular drug delivery system of Bromfenac Sodium. IJPSR 2014; 5:179-185.
  2. Kristiina J, Tomi J,Urtii A. Ocular absorption following drug delivery. Adv Drug Deliv Rev1995;16:3-19.
  3. Gambhire S, Bhalerao K, Singh S. In-situ Hydrogel: different approaches to Ocular Drug Delivery. Int J Pharm Pharm Sci 2013; 5: 27-36.
  4. Sreeraj M, Mitra AK, Hughes PM. In Mitra AK (ed). Text Book of Ophthalmic drug delivery systems. Missouri U.S.A., Marcel Deckker Inc. 2003;1-5.
  5. Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of Ciprofloxacin Hydrochloride. Drug Deliv 2003;10:185-191
  6. Schoenwald RD, Ward RL, Desantis LM, Rochrs RE. Influence of high viscosity vehicles on miotic effect of Pilocarpine. J.Pharm.Sci, 1978; 67: 1280-1284.
  7. Maurice DM, Srinivas SD. Use of flourimetry in assessing the? efficacy of a cation sensitive gel as an ophthalmic vehicle; comparison with scintigraphy. J.Pharm.Sci. 1992; 81: 615-619.
  8. Mishra DN, Gilhotra RM. Design and characterization of bioadhesive in situ gelling ocular inserts of Gatifloxacin sesquihydrate. DARU.2008; 16: 1-7.
  9. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release, 2007;122: 119-134.
  10. Bolanle L. Development of a Cysteamine in situ gelling system for the treatment of corneal crystals in cystinosis. University of London. London, 2008.
  11. Gurny R. Preliminary studies of porlonged acting drug delivery system for the treatment of glaucoma. Pharm Acta Helv, 1981;56:130-132.
  12. Naseem AC, Kohli K, Ali A. Preparation of in-situ froming ophthalmic gels of Ciprofloxacin Hydrochloride for the treatment of bacterial conjunctiviits:In vitro and in-vivo studies. J Pharm Sci, 2002;92:407-413.
  13. Sultana Y, Aquil M, Ali A. Ion-activated,Gelrite-based in situ ophthalmic gels of Pefloxacin Mesylate:comparison with conventional eye drops. Drug Deliv, 2006a; 13: 215-219.
  14. Srividya B, Rita M, Cardoza RM, Amin PD. Sustained ophthalmic delivery of Ofloxacin from a pH triggered in situ gelling system. J Control Release, 2001;73: 205-211.
  15. Mansour M, Mansour S, Mortada ND, Abd Elhady SS. Ocular poloxamer-based Ciprofloxacin Hydrochloride in situ forming gels. Drug Dev Ind Pharm, 2008; 34:744-752.
  16. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm, 2008;350: 247-256.
  17. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv, 2007;14: 507-515.
  18. Vadnere M, Amidon G, Lendenbaum S, Haslam JL. Thermodynamic study on the gel-sol transition of some Pluronic Polyols. Int. J. Pharm, 1984; 22: 207-218.
  19. Sultana Y, Aquil M, Ali D, Zafar S. Evaluation of Carbopol-Methyl Cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model, Pharm Dev Technol, 2006; 11: 313-319.
  20. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for Indomethacin. Acta Pharm, 2003;53: 251-261.
  21. Smadar C, Esther L, Amira T, Yael P. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release, 1997; 44: 201-208.
  22. Michelle C, Callegan BD, Novosad RT, Ramadan BW, Andrea L, Moyer. Rate of Bacterial Eradication by Ophthalmic Solutions of Fourth-Generation Fluoroquinolones. AdvTher, 2009; 26(4):447-454
  23. Spielmann H, HET-CAM test. Methods in Molecular Biology. ECVAM DB-ALM: INVITTOX protocol. FreieUniversit?t Berlin,1995:1-7
  24. Luepke NP. Hen's egg chorioallantoic membrane test for irritation potential. Food and chemical toxicology, 1985; 23(2): 287-291
  25. Spielmann H. Ocular irritation. In: Castell, Gomez-Lechon (Eds.): In vitro methods in pharmaceutical research. Academic Press, London 1997; 265-287
  26. Schlede E, Gerner I. The Draize eye test and progress in development and acceptance of alternatives to this test in Europe. In: Goldberg AM, van Zutphen LFM (Eds): The World Congress on Alternatives and Animals Use in the Life Sciences: Education, Research, Testing. Mary Ann Liebert, Inc., New York1995; 333-336
  27. Organization for Economic Co-Operation and Development (Ed.); OECD TG (405) for testing of chemicals. Acute eye irritation/corrosion; 2002
  28. Balls M, Brantom PG, Cassidy S, Esdaile D, Fentem J, Liebsch M, McPherson J, Pfannenbecker U, Prinsen M. Preliminary evaluation of the application of reference standards in the prevalidation and validation of in vitro test for eye irritation. In: DG Clark, SG Lisansky and R Macmillan: Alternatives to animal testing II, proceedings, Brussels. CPL Press, Berkshire1999 ; 201-204
  29. Steiling W. The Hen's EggTest on the Chorioallantoic Membrane (HET-CAM).; INVITTOX Protocol, 1994; 96
  30. Spielmann H. HET-CAM test Invittox Protocol 1992 ; 47
  31. Blein O, Adolphe M, Lakhdar B, Cambar J, Gubanski G, Castelli D, Contie C, Hubert F, Latrille F, Masson P, Clouzeau J, Bigot JF Le, Silva O De, Dossou KG. Correlation and validation of alternative methods to the Draize eye irritation test (OPAL project).Toxicology in vitro , 1991; 5(5-6): 555-557
  32. Hagino S, Kinoshita S, Tani N, Nakamura T, Ono N, Konishi K, Iimura H, Kojima H, Ohno Y. Inter laboratory validation of in vitro eye irritation tests for cosmetic ingredients. Chorioallantoic membrane (CAM) test. Toxicology in vitro, 1999; 13(1): 99-113
  33. Balls M, Botham PA, Bruner LH, Spielmann H. The EC/HO international validation study on alternatives to the Draize eye irritation test. Toxicology in vitro, 1995a; 9(6): 871-829
  34. Gupta H, Jain S, Rashi M, Pushpan M, Mishra AK. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv 2007;14: 507-515.
  35. Rupenthal ID. Ocular Delivery?of?Antisense Oligonucleotides using Colloidal Carriers:?Improving?the?wound repair after corneal surgery.?PhD Thesis The?University?of Auckland,?NewZealand?.20
  36. Laddha UD and Mahajan HS. An insight to ocular in situ gelling systems. 2017; 06(02): 31-40.

How to Cite This Article

Ankita Kapoor And G.D Gupta. (2019); HET CAM IRRITANCY STUDY FOR DEVELOPMENT OF GATIFLOXACIN IN SITU GEL FORMULATION., Int. J. of Adv. Res., 7 (05), 1218-1225, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/9154

Corresponding Author

Ankita Kapoor
PhD Research Scholar Pharmaceutics M.K. Gujral Punjab Technical University, Jalandhar
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.